Joseph Catanzaro
Stock Analyst at Mizuho
(3.95)
# 813
Out of 5,182 analysts
105
Total ratings
48.28%
Success rate
12.43%
Average return
Main Sectors:
Stocks Rated by Joseph Catanzaro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CLYM Climb Bio | Initiates: Outperform | $18 | $12.22 | +47.30% | 1 | Apr 15, 2026 | |
| APGE Apogee Therapeutics | Maintains: Outperform | $105 → $110 | $84.54 | +30.12% | 2 | Mar 30, 2026 | |
| CTMX CytomX Therapeutics | Maintains: Overweight | $10 → $12 | $4.13 | +190.56% | 7 | Mar 23, 2026 | |
| ERAS Erasca | Maintains: Outperform | $16 → $19 | $10.90 | +74.31% | 1 | Mar 13, 2026 | |
| TNGX Tango Therapeutics | Maintains: Outperform | $19 → $20 | $23.62 | -15.33% | 3 | Mar 11, 2026 | |
| EIKN Eikon Therapeutics | Initiates: Outperform | $26 | $9.97 | +160.78% | 1 | Mar 2, 2026 | |
| NRIX Nurix Therapeutics | Maintains: Overweight | $32 → $35 | $16.88 | +107.35% | 5 | Jan 29, 2026 | |
| IBRX ImmunityBio | Maintains: Overweight | $5 → $7 | $8.38 | -16.47% | 6 | Jan 20, 2026 | |
| RVMD Revolution Medicines | Maintains: Outperform | $90 → $143 | $151.07 | -5.34% | 4 | Jan 13, 2026 | |
| AVTX Avalo Therapeutics | Initiates: Outperform | $39 | $21.81 | +78.82% | 1 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $51 | $9.19 | +454.95% | 1 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $18 | $23.78 | -24.31% | 1 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $53 | $73.00 | -27.40% | 1 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $120 | $86.26 | +39.11% | 2 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $48 | $34.39 | +39.58% | 1 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $7.5 → $6 | $4.09 | +46.70% | 10 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $45 | $12.98 | +246.69% | 3 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $110 | $136.30 | -19.30% | 5 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $38 | $48.70 | -21.97% | 4 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $15 | $11.78 | +27.33% | 3 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $52 → $53 | $66.35 | -20.12% | 9 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $10 | $1.68 | +495.24% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $19 | $1.60 | +1,087.50% | 5 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $19 | $11.51 | +65.07% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $15 | $2.82 | +431.91% | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 | $9.68 | +271.90% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 | $9.71 | +54.48% | 4 | Jun 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $4.5 | $2.41 | +86.72% | 1 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $30 | $2.09 | +1,335.41% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.58 | +1,165.82% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $1.75 | $1.88 | -6.91% | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $30.52 | -34.47% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $1.5 | $2.48 | -39.52% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $240 → $200 | $26.02 | +668.64% | 2 | Mar 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $14.50 | +141.38% | 1 | Jun 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.46 | +4,009.59% | 1 | Mar 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $18 | $2.55 | +605.88% | 3 | Apr 7, 2020 |
Climb Bio
Apr 15, 2026
Initiates: Outperform
Price Target: $18
Current: $12.22
Upside: +47.30%
Apogee Therapeutics
Mar 30, 2026
Maintains: Outperform
Price Target: $105 → $110
Current: $84.54
Upside: +30.12%
CytomX Therapeutics
Mar 23, 2026
Maintains: Overweight
Price Target: $10 → $12
Current: $4.13
Upside: +190.56%
Erasca
Mar 13, 2026
Maintains: Outperform
Price Target: $16 → $19
Current: $10.90
Upside: +74.31%
Tango Therapeutics
Mar 11, 2026
Maintains: Outperform
Price Target: $19 → $20
Current: $23.62
Upside: -15.33%
Eikon Therapeutics
Mar 2, 2026
Initiates: Outperform
Price Target: $26
Current: $9.97
Upside: +160.78%
Nurix Therapeutics
Jan 29, 2026
Maintains: Overweight
Price Target: $32 → $35
Current: $16.88
Upside: +107.35%
ImmunityBio
Jan 20, 2026
Maintains: Overweight
Price Target: $5 → $7
Current: $8.38
Upside: -16.47%
Revolution Medicines
Jan 13, 2026
Maintains: Outperform
Price Target: $90 → $143
Current: $151.07
Upside: -5.34%
Avalo Therapeutics
Dec 18, 2025
Initiates: Outperform
Price Target: $39
Current: $21.81
Upside: +78.82%
Dec 18, 2025
Initiates: Outperform
Price Target: $51
Current: $9.19
Upside: +454.95%
Dec 18, 2025
Initiates: Neutral
Price Target: $18
Current: $23.78
Upside: -24.31%
Dec 18, 2025
Initiates: Outperform
Price Target: $53
Current: $73.00
Upside: -27.40%
Dec 11, 2025
Maintains: Outperform
Price Target: $81 → $120
Current: $86.26
Upside: +39.11%
Oct 21, 2025
Initiates: Outperform
Price Target: $48
Current: $34.39
Upside: +39.58%
Feb 28, 2025
Maintains: Neutral
Price Target: $7.5 → $6
Current: $4.09
Upside: +46.70%
Feb 27, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $12.98
Upside: +246.69%
Feb 12, 2025
Maintains: Overweight
Price Target: $105 → $110
Current: $136.30
Upside: -19.30%
Feb 12, 2025
Maintains: Overweight
Price Target: $37 → $38
Current: $48.70
Upside: -21.97%
Jan 17, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $11.78
Upside: +27.33%
Jan 10, 2025
Maintains: Neutral
Price Target: $52 → $53
Current: $66.35
Upside: -20.12%
Dec 13, 2024
Maintains: Overweight
Price Target: $7 → $10
Current: $1.68
Upside: +495.24%
Oct 31, 2024
Maintains: Overweight
Price Target: $10 → $19
Current: $1.60
Upside: +1,087.50%
Oct 7, 2024
Initiates: Overweight
Price Target: $19
Current: $11.51
Upside: +65.07%
Sep 23, 2024
Maintains: Overweight
Price Target: $12 → $15
Current: $2.82
Upside: +431.91%
Aug 15, 2024
Maintains: Overweight
Price Target: $36
Current: $9.68
Upside: +271.90%
Jun 14, 2024
Maintains: Overweight
Price Target: $15
Current: $9.71
Upside: +54.48%
May 16, 2024
Initiates: Overweight
Price Target: $4.5
Current: $2.41
Upside: +86.72%
Apr 25, 2024
Maintains: Overweight
Price Target: $26 → $30
Current: $2.09
Upside: +1,335.41%
Apr 22, 2024
Initiates: Overweight
Price Target: $20
Current: $1.58
Upside: +1,165.82%
May 23, 2023
Downgrades: Neutral
Price Target: $15 → $1.75
Current: $1.88
Upside: -6.91%
Dec 20, 2022
Maintains: Overweight
Price Target: $18 → $20
Current: $30.52
Upside: -34.47%
May 5, 2022
Downgrades: Neutral
Price Target: $25 → $1.5
Current: $2.48
Upside: -39.52%
Mar 10, 2022
Maintains: Overweight
Price Target: $240 → $200
Current: $26.02
Upside: +668.64%
Jun 21, 2021
Initiates: Overweight
Price Target: $35
Current: $14.50
Upside: +141.38%
Mar 25, 2021
Initiates: Overweight
Price Target: $60
Current: $1.46
Upside: +4,009.59%
Apr 7, 2020
Maintains: Overweight
Price Target: $28 → $18
Current: $2.55
Upside: +605.88%